UK markets closed
  • FTSE 100

    7,016.63
    +20.55 (+0.29%)
     
  • FTSE 250

    23,006.45
    +129.44 (+0.57%)
     
  • AIM

    1,242.61
    +11.50 (+0.93%)
     
  • GBP/EUR

    1.1755
    +0.0013 (+0.11%)
     
  • GBP/USD

    1.3884
    +0.0005 (+0.04%)
     
  • BTC-GBP

    28,562.62
    +918.80 (+3.32%)
     
  • CMC Crypto 200

    931.49
    +1.56 (+0.17%)
     
  • S&P 500

    4,404.88
    +3.42 (+0.08%)
     
  • DOW

    35,022.94
    -35.58 (-0.10%)
     
  • CRUDE OIL

    72.16
    +0.51 (+0.71%)
     
  • GOLD FUTURES

    1,799.70
    -0.10 (-0.01%)
     
  • NIKKEI 225

    27,581.66
    -388.56 (-1.39%)
     
  • HANG SENG

    25,473.88
    +387.45 (+1.54%)
     
  • DAX

    15,570.36
    +51.23 (+0.33%)
     
  • CAC 40

    6,609.31
    +77.39 (+1.18%)
     

Global Non-hormonal Therapies for Women's Health Market Report 2021-2030: Current Market Landscape with Focus on Prescription Drugs & Future Potential of this Evolving Market

·6-min read

Dublin, July 20, 2021 (GLOBE NEWSWIRE) -- The "Non-hormonal Therapies for Women's Health Market by Target Indication, Type of Molecule, Purpose of Therapy, Mechanism of Action, Route of Administration, and Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

"Non-hormonal Therapies for Women's Health Market 2021-2030" report features an extensive study of the current market landscape of non-hormonal therapies, primarily focusing on prescription drugs. The study also includes an elaborate discussion on the future potential of this evolving market.

One of the key objectives of the report was to estimate the existing market size and the future opportunity associated with non-hormonal therapies, over the next decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the evolution of the market for the period 2021-2030.

In recent years, the development and introduction of non-hormonal alternatives has revolutionized women's healthcare. Brisdelle was the first of such products, approved in 2013 for the management of hot flashes in menopausal women. Till date, 21 non-hormonal therapies (recent examples include OriahnnT, PhexxiT and Esmya) have been approved. Further, several such non-hormonal product candidates are under evaluation across different stages of product development.

The inherent advantages of non-hormonal therapies, such as better safety profile, ability to maintain hormonal balance and relatively short treatment courses, over their hormonal counterparts have been demonstrated both in clinical trials and post product approval studies. As a result, such products are currently preferred over hormone-based therapies, and the non-hormonal therapy pipeline is expected to continue to steadily expand over the coming years.

It is worth highlighting that significant partnership activity has been observed in this market, with several stakeholders entering into strategic collaborations to support the ongoing product development and commercialization initiatives of such products. In the foreseen future, promising results from the ongoing clinical research initiatives are likely to bring in more investments to support product development activity in this upcoming market segment. Therefore, we are led to anticipate significant growth in this domain in the coming years.

Scope of the Report

Amongst other elements, the report features:

  • A detailed review of the overall market landscape of non-hormonal therapies, including information on their current phase of development (marketed, clinical, preclinical and discovery), type of molecule (biologic and small molecule),target indication (bacterial vaginosis, contraception, endometriosis, postmenopausal osteoporosis, uterine fibroids, vaginitis and others), purpose of therapy (treatment of disease and management of symptoms), target women population (adult, postmenarchal and premenopausal female, postmenopausal female), mechanism of action (antagonists, agonists, inhibitors and modulators), route of administration (intramuscular, intravaginal, intravenous, oral, subcutaneous, topical, transdermal and others) and special drug designation(s)awarded (if any).

  • A detailed review of the players engaged in the development of non-hormonal therapies, along with information on their year of establishment, company size, location of headquarters and regional landscape.

  • An elaborate discussion on the various commercialization strategies that can be adopted by drug developers engaged in this domain, across different stages of therapy development, including prior to drug launch, at/during drug launch and post-marketing of the drug.

  • Detailed profiles of phase III non-hormonal therapies. Each drug profile features a brief overview of the therapy, along with information on their current development status, route of administration, primary target indication, dosage, mechanism of action, clinical trials, clinical trial results, collaborations and special drug designation(s) received(if any).

  • A detailed geographical clinical trial analysis of completed and ongoing studies of non-hormonal therapies, based on several relevant parameters, such as trial registration year, trial status, trial phase, target indication, geography, type of sponsor, prominent treatment sites and enrolled patient population.

  • An analysis of the various partnerships that have been inked by stakeholders engaged in the development of non-hormonal therapies, during the period pre2013-2020, including research agreements, research and development agreements, contract manufacturing agreements, licensing agreements and other relevant types of deals. It further features a detailed analysis of the investments made, including award/grant, seed financing, venture capital financing, debt financing and others, in companies engaged in this domain.

Key Questions Answered

  • Who are the leading industry players engaged in the development of non-hormonal therapies?

  • How many non-hormonal therapy candidates form the current development pipeline? Which key women's health related disease indications are targeted by such products?

  • Which commercialization strategies are most commonly adopted by non-hormonal therapy developers, across different stages of product development?

  • Which partnership models are commonly adopted by stakeholders engaged in this domain?

  • What are the key value drivers of the merger and acquisition activity in the non-hormonal therapies industry?

  • Who are the key stakeholders that have actively made investments in the non-hormonal therapies domain?

  • How is the current and future market opportunity likely to be distributed across key market segments?

Companies Mentioned

  • AbbVie

  • Actavis

  • Adjuvant Capital

  • Aisling Capital

  • Allergan

  • Amgen

  • Amplity Health

  • Arcadia Securities

  • Aspire Capital Fund

  • Astellas Pharma

  • Avomeen

  • Azure Biotech

  • Bayer

  • BB Biotech

  • Boehringer Ingelheim

  • Broadfin Capital

  • Brookline Capital Markets

  • Cantor Fitzgerald

  • Ceek Women's Health

  • Celmatix

  • Chugai Pharmaceutical

  • Cidara Therapeutics

  • DAFNA Capital Management

  • Dare Bioscience

  • Duchesnay

  • Eli Lilly

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

  • Evofem Biosciences

  • Evotec

  • Exeltis

  • Ferring Pharmaceuticals

  • First Manhattan Co.

  • Forest Laboratories

  • Fougera Pharmaceuticals

  • Gedea Biotech

  • Gedeon Richter

  • Ghost Tree Capital

  • Great Point Partners

  • Guggenheim Securities

  • H.C. Wainwright & Co.

  • Hammock Pharmaceuticals (acquired by Element Nutritional Sciences)

  • Hansoh Pharma

  • Health Decisions

  • Hennepin Life Sciences

  • Inmunotek

  • Inovio Pharmaceuticals

  • Intralytix, the Eliava Foundation

  • ITF Pharma

  • Jiangsu Hengrui Medicine

  • KaNDy Therapeutics (acquired by Bayer)

  • Kindeva Drug Delivery

  • Kissei Pharmaceutical

  • Korea Investment Partners (KIP)

  • Ladenburg Thalmann

  • Ligand Pharmaceuticals

  • Lupin Pharmaceuticals

  • Medtech4Health

  • Merck Sharp & Dohme

  • Milana Pharm

  • Mitsubishi Tanabe Pharma

  • Medical Research Commercialisation Fund (MRCF)

  • Mycovia Pharmaceuticals

  • Myovant Sciences

  • National Holdings

  • National Securities Corporation

  • Neurocrine Biosciences

  • New Enterprise Associates

  • New Leaf Venture Partners

  • NovaDigm Therapeutics

  • Novartis Pharmaceuticals

  • Noven Pharmaceuticals

  • ObsEva

  • Ogeda

  • Omega Funds

  • Oxford Finance

  • PDL BioPharma

  • Pfizer

  • Prosight Capital

  • Puissance Capital

  • QUE Oncology

  • Radius Health

  • Repros Therapeutics (acquired by Allergan)

  • Roche

  • Sanofi-Aventis

  • SCYNEXIS

  • Shionogi

  • Sofinnova Ventures

  • Sphera Global Healthcare Fund

  • Square 1 Bank

  • Starpharma

  • Strategic Science & Technologies

  • Sumitomo Dainippon Pharma

  • Swelife

  • Symbiomix Therapeutics (acquired by Lupin)

  • Takeda Pharmaceutical

  • TriLogic Pharma

  • Uniseed

  • Venrock Healthcare Capital Partners

  • Vinnova Financing

  • Vinnova Grants

  • WBB Securities

  • Woodford Investment Management

  • Xanodyne Pharmaceuticals

  • Yaso Therapeutics

Non-hormonal Therapies for Women's Health Market: Product Wise Sales Forecasts

  • NuvessaT (Metronidazole)

  • VivaGelT (SPL 7013)

  • SolosecT (Secnidazole)

  • TymlosT (Abaloparatide)

  • OrilissaT

  • Osphena (Ospemifene)

  • EvenityT(Romosozumab-aqqg)

  • Esmya and Fibristal (Ulipristal acetate)

  • PhexxiT (Amphora)

  • OriahnnT

  • Relugolix

  • DARE-BV1 (Clindamycin gel)

  • Ovaprene

  • Yselty (Linzagolix)

  • Fezolinetant

  • BAY1002670 (Vilaprisan)

  • Abaloparatide-TD

  • Terconazole(0.4%)

  • SCY-078 (Ibrexafungerp)

  • VT-1161 (Oteseconazole)

  • MV140 (Uromune)

  • EVO100

For more information about this report visit https://www.researchandmarkets.com/r/jsbi5w

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting